medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2010, Number 5

<< Back Next >>

Rev Invest Clin 2010; 62 (5)

Prevalence of posttransplant hypertension in pediatric kidney transplant recipients: Effect on long term allograft survival

Hernández-Infante E, García-Martínez C, Beltrán-de-la-Luz S, Reyes-Acevedo R, Romo-Franco L, Delgadillo-Castañeda R, Orozco-Loza I, Chew-Wong A

Language: Spanish
References: 31
Page: 398-405
PDF size: 76.89 Kb.


ABSTRACT

Background. Arterial hypertension after renal transplantation has been identified as an adverse factor over the long term allograft function, thus identification and treatment of this entity has an impact on graft survival, as in patient survival. Studies about pediatric receptor populations have reported a prevalence of hypertension after renal transplantation ranging from 58 to 90%. In Mexico, the pre-valence of arterial hypertension after renal transplantation has been reported as 71% for an adult population attending a main hospital center in Mexico. No pediatric receptor studies in Mexico have reported the prevalence of hypertension after renal transplantation so far. The purpose of our study was to document the prevalence of arterial hypertension after renal transplantation in pediatric receptors, as well as its impact on allograft survival on a long term basis. Material and methods. We performed a retrospective analysis among pediatric patients who underwent renal transplantation at our center, Centenario Hospital Miguel Hidalgo, between years 2000 to 2006. Results. A total of 111 pediatric renal transplantation receptors were included, among whom 56 patients were classified as hypertensive (HT) and 54 patients were classified as nomotensive (NT) (one patient had to be excluded due to early allograft dysfunction). The mean age at the time of transplantation for the population under study was 14 ± 3 years, with a predominance of male gender over females (1.5:1). In 89% of the transplantations, the source of the allograft was a living donor. The prevalence of arterial hypertension after renal transplantation in our population was 50.5%. Among patients in the HT group at least an episode of acute rejection presented in 8.9% (n = 5) of the cases, compared to only 3.7% (n = 2) of patients in the NT group with an episode of acute rejection. Likewise, the prevalence of chronic allograft nephropathy detected in the HT group was 11% (n = 6) vs. 7% (n = 4) in the NT group. The mean serum creatinine levels were 1.0 ± 0.4 mg/dL for the HT group and 0.9 ± 0.3 mg/dL for the NT group at the first month followup, however mean serum creatinine levels addressed at the last consult were different among groups: 1.7 ± 1.8 mg/dL for the HT group versus 1.1 ± 0.5 mg/dL for the NT group. Patient survival was similar for both groups (98%) and the follow-up period was also similar, being 39 ± 12 months for the HT group and 39 ± 17 months for the NT group. The multivariate Cox proportional hazard analysis demonstrated that the number of antihypertensive drugs needed to achieve the control of blood pressure, and the presence of chronic allograft nephropathy, were the independent risk factors associated to a graft loss at long term. Conclusion. The prevalence of hypertension after renal transplantation in our pediatric population was 50.5%, which is clearly towards the inferior limit of the reported prevalence in other studies (50-90%). The tight control of blood pressure is an intervention that may have a significant impact on graft survival at long term. In our study, the severity of arterial hypertension after renal transplantation represented as the number of antihypertensive drugs needed to achieve control of blood pressure, as well as the presence of chronic allograft nephropathy, were the factors associated to long term graft loss.


REFERENCES

  1. Baluarte HJ, Gruskin AB, Ingelfinger JR, Stablein D, Tejani A. Analysis of hypertension in children post renal transplantation- a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol 1994; 8: 570-3.

  2. Sorof JM, Sullivan EK, Tejani A, Portman RJ. Antihypertensive medication and renal allograft failure: A North American Pediatric Renal Transplant Cooperative Study report. J Am Soc Nephrol 1999; 10: 1324-30.

  3. Seeman T. Hipertensión after renal transplantation. Pediatr Nephrol DOI 10.1007/s00467-007-0627-7.

  4. Chew-Wong A, Alberú-Gómez J, Abasta-Jiménez M, Márquez- Días F, Correa-Rotter R. Hipertensión arterial postrasplante renal: factores de riesgo asociados e influencia en la supervivencia del injerto renal. Gac Méd Méx 2005; 41: 6.

  5. Mitsnefes MM. Hypertension and end-organ damage in pediatric renal transplantation. Pediatr Transplant 2004: 8; 394-9.

  6. Groothoff JW, Lilien MR, van de Kar NC, Wolff ED, Davin JC. Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatr Nephrol 2005; 20(3): 374-9.

  7. Mitsnefes MM. Cardiovascular morbidity and mortality in children with chronic kidney disease in North America: lessons from the USRDS and NAPRTCS databases. Perit Dial Int 2005; 25(Suppl. 3): 120-2.

  8. Nankivell BJ, Borrows RJ, Chir B, Fung C, O’Connell PJ, Allen RDM, Chapman JR. The Natural History of Chronic Allograft Nephropathy. N Engl J Med 2003; 349: 2326-33.

  9. Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O, Jr. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72: 13-21.

  10. Silverstein DM, Mitchell M, LeBlanc P, Boudreaux JP. Assessment of risk factors for cardiovascular disease in pediatric renal transplant patients. Pediatr Transplantation 2007; 11: 721-9.

  11. Atkinson P, Filler G. New trends in immunosuppression for pediatric renal transplant recipients. Curr Opin Organ Transplant 2007; 12: 509-14.

  12. Neu AM, Ho PL, Fine RN, Furth SL, Fivush BA. Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study. Pediatr Transplant 2003; 7: 217-22.

  13. Irish W, Sherrill B, Brennan DC, Lowell J, Schnitzler M. Three-year posttransplant graft survival in renal transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen Transplantation: 2003; 76(12): 1686-90.

  14. Seikaly M, HO P-L, Emmett L, Tejani A. The 12th annual report of the North American Pediatric Renal Transplant Cooperative Study: Renal transplantation from 1987 through 1998. Pediatr Transplant 2001; 5: 215-31.

  15. Nagasako SS, Koch Nogueira PC, Machado PGP, Medina Pestana JO. Arterial hypertension following renal transplantation in children-a short-term study. Pediatr Nephrol 2003; 18: 1270-4.

  16. EL-Husseini AA, Foda MA, Shokeir AA, Shehab EL-Din AB, Sobh MA, Ghoneim MA. Determinants of graft survival in pediatric and adolescent live donor kidney transplant recipients: A single center experience. Pediatr Transplant 2005; 9: 763-9.

  17. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331: 365-76.

  18. Giral M, Nguyen JM, Karam G, et al. Impact of graft mass on the clinical outcome of kidney transplants. J Am Soc Nephrol 2005; 16: 261-8.

  19. Opelz G, Döhler B. Collaborative Transplant Study Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5(11): 2725-31.

  20. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 2004; 114: 555-76.

  21. Ducloux D, Motte G, Kribs M, Abdelfatah AB, Bresson-Vautrin C, Rebibou JM, Chalopin JM. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol 2002; 57(6): 409-13.

  22. Béji S, Abderrahim E, Kaaroud H, Jebali H, Ben Abdallah T, El Younsi F, Ben Moussa F, et al. Risk factors of arterial hypertension after renal transplantation. Transplant Proc 2007; 39(8): 2580-2.

  23. Ferraris JR, Ghezzi L, Waisman G, Krmar RT. Potential cardiovascular risk factors in paediatric renal transplant recipients. Pediatr Nephrol 2006; 21: 119-25.

  24. Tejani A, Sullivan EK: The impact of acute rejection on chronic rejection: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2000; 4: 107-11.

  25. Alexander SI, Fletcher JT, Nankivell B. Chronic allograft nephropathy in paediatric renal transplantation. Pediatr Nephrol 2007; 22: 17-23.

  26. Silverstein DM, LeBlanc P, Hempe JM, Ramcharan T, Boudreaux JP. Tracking of blood pressure and its impact on graft function in pediatric renal transplant patients. Pediatr Transplant 2007; 11: 860-7.

  27. Mitsnefes MM, Khoury PR, Mcenery PT. Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients. J Pediatr 2003; 143: 98-103.

  28. Mitsnefes MM, Omalaja A, Mcenery PT. Short-term pediatric renal transplant survival: Blood pressure and allograft function. Pediatr Transplant 2001; 5: 160-5.

  29. Ruggenenti P, Perna A, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzzi G. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-11.

  30. Walker WG: Hypertension-related renal injury: A major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22: 164-73.

  31. Shapiro R. Living donor kidney transplantation in pediatric recipients. Pediatr Transplant 2006; 10: 844-50.




2020     |     www.medigraphic.com